Toripalimab
- Generic Name
- Toripalimab
- Brand Names
- Loqtorzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1924598-82-2
- Unique Ingredient Identifier
- 8JXN261VVA
- Background
Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).
- Indication
⑴用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。⑵用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌（NPC）。⑶用于治疗既往接受过治疗的局部进展或转移性尿路上皮癌（UC）。⑷用于食管鳞癌一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2019-06-20
- Lead Sponsor
- Peking University
- Target Recruit Count
- 336
- Registration Number
- NCT03992911
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- Jiangmen Central Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03982680
- Locations
- 🇨🇳
Jiangmen central hospital, Jiangmen, Guangdong, China
Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- Di Wu
- Target Recruit Count
- 25
- Registration Number
- NCT03946943
- Locations
- 🇨🇳
First Hospital of Jilin University, Chang chun, Jilin, China
Phase II Study of Toripalimab Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometastasis
- Conditions
- Interventions
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT03927898
- Locations
- 🇨🇳
Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Phase II of Lenvatinib Plus Toripalimab for Advanced HCC
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2019-06-03
- Lead Sponsor
- Sun Yat-sen University
- Registration Number
- NCT03919383
- Locations
- 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
Thermal Ablation Followed by Immunotherapy for HCC
- Conditions
- Interventions
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- Xiangya Hospital of Central South University
- Target Recruit Count
- 145
- Registration Number
- NCT03864211
- Locations
- 🇨🇳
Xiangya Hospital, Central South University, Changsha, Hunan, China
Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Target Recruit Count
- 514
- Registration Number
- NCT03829969
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 43
- Registration Number
- NCT03811379
- Locations
- 🇨🇳
Cancer center of Sun Yat-sen University, Guangzhou, Guangdong, China
Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 35
- Registration Number
- NCT03810339
- Locations
- 🇨🇳
Cancer center of Sun Yat-sen University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.